resTORbio to Present at Upcoming Investor Conferences in November
November 07, 2018 08:00 ET
|
resTORbio, Inc.
BOSTON, Nov. 07, 2018 (GLOBE NEWSWIRE) -- resTORbio, Inc. (Nasdaq: TORC), a clinical-stage biopharmaceutical company focused on helping people live healthier longer through the development and...
resTORbio Appoints Michael Grissinger to its Board of Directors
November 06, 2018 08:00 ET
|
resTORbio, Inc.
- Brings extensive business development and licensing experience to resTORbio’s Board - BOSTON, Nov. 06, 2018 (GLOBE NEWSWIRE) -- resTORbio, Inc. (Nasdaq: TORC), a clinical-stage biopharmaceutical...
resTORbio Announces Additional RTB101 Phase 2b Data Demonstrating Decreased Incidence of Laboratory-Confirmed RTIs with Severe Symptoms, Total Infections and UTIs
October 16, 2018 07:12 ET
|
resTORbio, Inc.
RTB101 10 mg once daily decreased incidence of laboratory-confirmed respiratory tract infections (RTIs) with severe symptoms by 52.1% vs. placebo (p=0.034) In addition to decreasing the incidence of...
resTORbio to Present at 2018 Cantor Fitzgerald Global Healthcare Conference
September 24, 2018 08:00 ET
|
resTORbio, Inc.
BOSTON, Sept. 24, 2018 (GLOBE NEWSWIRE) -- resTORbio, Inc. (Nasdaq: TORC), a clinical-stage biopharmaceutical company focused on helping people live healthier longer through the development and...
resTORbio Appoints Meredith Manning as Chief Commercial Officer
September 18, 2018 08:00 ET
|
resTORbio, Inc.
BOSTON, Sept. 18, 2018 (GLOBE NEWSWIRE) -- resTORbio, Inc. (Nasdaq:TORC), a clinical biopharmaceutical company focused on helping people live healthier longer through the development and...
resTORbio to Present at Wells Fargo 2018 Healthcare Conference
August 29, 2018 08:00 ET
|
resTORbio, Inc.
BOSTON, Aug. 29, 2018 (GLOBE NEWSWIRE) -- resTORbio, Inc. (Nasdaq: TORC), a clinical-stage biopharmaceutical company focused on helping people live healthier longer through the development and...
resTORbio Appoints Jeffrey Chodakewitz, M.D., to its Board of Directors
August 15, 2018 08:00 ET
|
resTORbio, Inc.
BOSTON, Aug. 15, 2018 (GLOBE NEWSWIRE) -- resTORbio, Inc. (Nasdaq:TORC), a clinical-stage biopharmaceutical company focused on helping people live healthier longer through the development and...
resTORbio Reports Second Quarter 2018 Financial Results
August 09, 2018 08:00 ET
|
resTORbio, Inc.
Phase 2b results identify dose and patient population for pivotal program with RTB101 Initiation of pivotal program with RTB101 expected in the first half of 2019 BOSTON, Aug. 09, 2018 (GLOBE...
resTORbio to Present at the Canaccord Genuity 38th Annual Growth Conference
July 30, 2018 07:00 ET
|
resTORbio, Inc.
BOSTON, July 30, 2018 (GLOBE NEWSWIRE) -- resTORbio, Inc. (Nasdaq: TORC), a clinical-stage biopharmaceutical company focused on helping people live healthier longer through the development and...
resTORbio Announces Positive Topline Results in Phase 2b Trial of RTB101
July 25, 2018 07:00 ET
|
resTORbio, Inc.
-- Statistically significant and clinically meaningful 30.6% reduction in the percentage of patients with one or more laboratory-confirmed respiratory tract infections (RTIs), the primary endpoint of...